La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Allakos a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Allakos..

Allakos (NASDAQ:ALLK) Azioni, Catena delle Opzioni

Allakos

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.

Allakos Inc

Allkem Ltd

Genie Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNE#NYSE">GNE</a>) reported quarterly earnings of $0.41 per share. This is a 22.64 percent decrease over earnings of $0.53 per share from the same period last year. The company reported $111.92 million in sales this quarter. This is a 10.47 percent decrease over sales of $125.00 million the same period last year.

Earnings

News

Genie Energy Q3 EPS $0.41 Down From $0.53 YoY, Sales $111.92M Down From $125.00M YoY

Kornit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNT#NASDAQ">KRNT</a>) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.07 by 57.14 percent. The company reported quarterly sales of $50.732 million which beat the analyst consensus estimate of $50.468 million by 0.52 percent. This is a 14.34 percent decrease over sales of $59.224 million the same period last year.

Earnings Beats

KRNT

Kornit Digital Q3 2024 Adj. EPS $0.11 Beats $0.07 Estimate, Sales $50.732M Beat $50.468M Estimate

Barclays analyst Jiong Shao initiates coverage on Tencent Music Enter Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>) with a Overweight rating and announces Price Target of $16.

Price Target

Initiation

Analyst Ratings

Barclays Initiates Coverage On Tencent Music Enter Gr with Overweight Rating, Announces Price Target of $16

MCFT

MasterCraft Boat Hldgs Q1 2025 Adj. EPS $0.12 Beats $0.03 Estimate, Sales $65.400M Beat $61.181M Estimate

Morgan Stanley analyst James Faucette maintains Broadridge Financial Soln (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BR#NYSE">BR</a>) with a Equal-Weight and raises the price target from $200 to $207.

Morgan Stanley Maintains Equal-Weight on Broadridge Financial Soln, Raises Price Target to $207

Earnings Misses

Brink's Q3 2024 Adj. EPS $1.51 Misses $1.79 Estimate, Sales $1.260B Miss $1.275B Estimate

Orion Energy Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OESX#NASDAQ">OESX</a>) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.07) by 57.14 percent. The company reported quarterly sales of $19.361 million which missed the analyst consensus estimate of $22.161 million by 12.64 percent. This is a 5.95 percent decrease over sales of $20.586 million the same period last year.

OESX

Orion Energy Sys Q2 2025 GAAP EPS $(0.11) Misses $(0.07) Estimate, Sales $19.361M Miss $22.161M Estimate

Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $0.02 by 650 percent. This is a 73.17 percent increase over losses of $(0.41) per share from the same period last year. The company reported quarterly sales of $4.35 million which missed the analyst consensus estimate of $7.12 million by 38.95 percent. This is a 53.18 percent decrease over sales of $9.28 million the same period last year.

ACRS

Aclaris Therapeutics Q3 2024 GAAP EPS $(0.11) Misses $0.02 Estimate, Sales $4.35M Miss $7.12M Estimate

On Wednesday, Janover Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JNVR#NASDAQ">JNVR</a>) announced its financial results for the third quarter ended September 30, 2024.
Revenue for the three months ended September 30, 2024, was approximately $619,000, up 6% from the previous year. Revenue increased sequentially by approximately 40%.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/11/41710716/exclusive-janover-scores-new-deal-with-real-estate-firm-for-ai-client-engagement-tools" rel="noreferrer noopener">EXCLUSIVE: Janover Scores New Deal With Real Estate Firm For AI Client Engagement Tools</a>
During fiscal 2024, Janover focused on more considerable loan opportunities, which should increase its average loan size.
With the acquisition of Groundbreaker and the recent launch of Insurtech, an increasing portion of Janover&#8217;s total revenue will be recurring revenue, where it will receive annual, quarterly, and monthly subscriptions, as well as yearly insurance premium commissions.
For the quarter ended September 30, 2024, approximately 22% of Janover&#8217;s total revenue was recurring revenue compared to 20% Q/Q. The company said it will continue to migrate its revenue to recurring and subscription revenue for the remainder of fiscal 2024 and beyond.&nbsp;&nbsp;
Subscription revenue was approximately $134,000 for the September 30, 2024 quarter, increasing sequentially by approximately 51%. Janover&#8217;s annual recurring revenue run rate reached roughly $480,000 for the September 30, 2024 quarter.&nbsp;
ARR increased sequentially by approximately 58%. ARR represents an annualization of its recurring revenue, which assumes a full year of revenue.
Net loss for the three months ended September 30, 2024, was approximately $471,000, a decrease of approximately 70%. Net loss for the three months ended September 30, 2024, decreased sequentially by approximately 41%.
Quarterly Business Highlights:
<ul>
<li>Janover Pro: Launched as a matching tool for commercial real estate loans, connecting professionals with over 1,000 lenders, including more than 10% of U.S. banks.</li>
<li>Janover Insurance Group: Achieved another profitable quarter, with run rate recurring revenue increasing by 89% quarter-over-quarter.</li>
<li>Janover Engage: Initiated the pilot of an equity marketplace connecting real estate syndicators and over 40,000 accredited investors who have collectively invested more than $1 billion.</li>
<li>Janover Connect: Rebranded and relaunched as the user-friendly real estate syndication software and investor portal for syndicators and GPs.</li>
<li>Janover Capital Markets: The debt placement team set a new revenue record for new business revenue in a single quarter.</li>
<li>Janover AI: Its conversational AI applications are now licensed by two publicly traded companies to enhance operational efficiency.</li>
</ul>
Janover&#8217;s CEO, Blake Janover, highlighted a milestone quarter, noting it as the strongest since their IPO and marking a third consecutive period of simultaneous gains in revenue, net income, cash flow, adjusted EBITDA, and ARR.
Price Action: JNVR stock closed higher by 3.82% at $0.5623 at Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41043484/exclusive-janover-enhances-insurtech-subsidiary-with-ai-powered-sales-and-engagement-tools" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Janover Enhances Insurtech Subsidiary with AI-Powered Sales and Engagement Tools</a></li>
</ul>

Fintech news covering the emerging Financial Technology services sector

Fintech

Exclusives

Tech

JNVR

EXCLUSIVE: Janover's Q3 Revenue Rises 6%, CEO Eyes Boost in Recurring Sales and Larger Loans

Market-Moving Exclusives

Janover Q3 2024 Revenue $618.7K Vs $583.76K YoY, EPS $(0.04) Vs $(0.17) YoY

2024 Guidance
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">Q4 2024 Guidance</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">FY 2024 Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1">Baseline</td>
<td colspan="1" rowspan="1">High</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1">Baseline</td>
<td colspan="1" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">$1.850B</td>
<td colspan="1" rowspan="1">$1.870B</td>
<td colspan="1" rowspan="1">$1.890B</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$7.390B</td>
<td colspan="1" rowspan="1">$7.410B</td>
<td colspan="1" rowspan="1">$7.430B</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adj. EBITDA&#x2A;1</td>
<td colspan="1" rowspan="1">$478M</td>
<td colspan="1" rowspan="1">$488M</td>
<td colspan="1" rowspan="1">$498M</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$1.885B</td>
<td colspan="1" rowspan="1">$1.895B</td>
<td colspan="1" rowspan="1">$1.905B</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adj. EBITDA Margin&#x2A;1</td>
<td colspan="1" rowspan="1">25.8%</td>
<td colspan="1" rowspan="1">26.1%</td>
<td colspan="1" rowspan="1">26.3%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">25.5%</td>
<td colspan="1" rowspan="1">25.6%</td>
<td colspan="1" rowspan="1">25.6%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adj. Earnings per Share&#x2A;1</td>
<td colspan="1" rowspan="1">$0.70</td>
<td colspan="1" rowspan="1">$0.71</td>
<td colspan="1" rowspan="1">$0.72</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$2.65</td>
<td colspan="1" rowspan="1">$2.66</td>
<td colspan="1" rowspan="1">$2.67</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow1</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$890M</td>
<td colspan="1" rowspan="1">$920M</td>
<td colspan="1" rowspan="1">$940M</td>
</tr>
</tbody>
</table>
</figure>

Guidance

Howmet Aerospace Sees Q4 Revenue Of $1.85B-$1.89B Vs. $1.89B Est.; Adj. EPS Of $0.70-$0.72 Vs. $0.69 Est.

Shares of Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) experienced a significant drop of 22.74% in pre-market trading on Wednesday as per <a href="https://pro.benzinga.com">Benzinga Pro</a>. This decline comes after the company reported revenue that fell short of expectations and issued weaker-than-expected guidance. Furthermore, Super Micro has announced uncertainty regarding the filing of its annual results for the latest fiscal year.
What Happened: The company&#8217;s shares had already been under pressure last week following the <a href="https://www.benzinga.com/news/earnings/24/11/41750022/super-micro-computer-stock-is-in-the-spotlight-ahead-of-q1-earnings-whats-going-on">resignation of its auditor</a>, Ernst &amp; Young, amid allegations of accounting irregularities and claims of shipping sensitive chips to sanctioned entities, potentially violating export controls. During a call with analysts on Tuesday, Super Micro did not address questions regarding Ernst &amp; Young&#8217;s resignation or corporate governance issues. CEO Charles Liang mentioned that the company is actively seeking a new auditor.
Super Micro faces a potential delisting from the Nasdaq if it does not submit its annual report to the SEC by mid-November. The company has not released audited results since May. Liang stressed the importance of updating their financial reporting. For the quarter ending Sep. 30, Super Micro reported net sales between $5.9 billion and $6 billion, which fell short of the $6.45 billion analyst expectations but represented an 181% annual increase.
See Also: <a href="https://www.benzinga.com/markets/equities/24/11/41703265/haley-tells-pennsylvania-voters-to-put-emotion-aside-and-rally-behind-trump?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Haley Tells Pennsylvania Voters To Put Emotion Aside And Rally Behind Trump</a>
Despite these challenges, Super Micro&#8217;s business has been thriving, driven by demand for servers equipped with Nvidia processors for AI applications. However, the company&#8217;s forecast for the December quarter also fell below estimates, projecting revenue between $5.5 billion and $6.1 billion, compared to the $6.86 billion average analyst estimate. Adjusted earnings per share are expected to be between 56 cents and 65 cents, below the anticipated 83 cents.
Why It Matters: The recent resignation of Ernst &amp; Young as Super Micro&#8217;s auditor has put the company under intense scrutiny. The auditor, appointed in March 2023, resigned before completing its report on the company&#8217;s financials or internal controls. This resignation has raised significant concerns about governance and transparency at Super Micro, contributing to the stock&#8217;s volatility. The company&#8217;s inability to address these issues could have long-term implications for its market position and investor confidence.
Meanwhile, <a href="https://www.benzinga.com/news/earnings/24/11/41769412/dow-nasdaq-futures-race-higher-as-trump-wins-white-house-djt-tesla-shares-surge-veteran-investor-pr">U.S. stocks could witness a strong opening </a>on Wednesday after former President Donald Trump <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election" target="_blank" rel="noreferrer noopener">emerged victorious</a> after a long-drawn battle with Joe Biden and Kamala Harris. In premarket trading on Wednesday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) gained 2.33% to $590.23 and the Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 1.82% to $501.15, according to <a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41704760/bitcoin-ethereum-dogecoin-reverse-as-trumps-odds-fall-on-betting-markets-trader-says-bull-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Reverse As Trump&#8217;s Odds Fall On Betting Markets: Trader Says &#8216;Bull Run Will Begin&#8217; For This Crypto After The Election</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Equities

Pre-Market Outlook

Markets

General

SMCI

Super Micro Computer Shares Plummet 22.7% In An Otherwise Green Pre-Market: What's Going On?

SGHC

Super Group Q3 Revenue €402.9M, Profit €8.5M

Leerink Partners analyst Rick Bienkowski upgrades Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) from Market Perform to Outperform and raises the price target from $27 to $39.

Upgrades

BEAM

Leerink Partners Upgrades Beam Therapeutics to Outperform, Raises Price Target to $39

DJT: 61% &#x7C; <a href="https://www.benzinga.com//node/41769412">Dow, Nasdaq Futures Race Higher As Trump Wins White House: DJT, Tesla Shares Surge — Veteran Investor Predicts US Economy Could 'Take Off'</a>
&nbsp;
QLYS: 20% &#x7C; <a href="https://www.benzinga.com//node/41770315">Qualys shares are trading higher after the company reported better-than-expected Q3 financial results, raised its FY24 guidance, and issued Q4 revenue guidance above estimates.</a>
&nbsp;
PACS: -23% &#x7C; <a href="https://www.benzinga.com//node/41768760">PACS Group shares are trading lower after the company announced postponement of Q3 results and disclosure on civil investigative demands from the federal government.</a>

Movers

Trading Ideas

PACS

QLYS

Market-Moving News for November 6th

Morgan Stanley analyst James Quigley maintains Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) with a Equal-Weight and raises the price target from $45 to $49.

KYMR

Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Raises Price Target to $49

Morgan Stanley analyst Judah Frommer maintains Arcellx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) with a Overweight and raises the price target from $81 to $106.

ACLX

Morgan Stanley Maintains Overweight on Arcellx, Raises Price Target to $106

Morgan Stanley analyst Vincent Andrews maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Equal-Weight and lowers the price target from $140 to $100.

Morgan Stanley Maintains Equal-Weight on Celanese, Lowers Price Target to $100

JP Morgan analyst Lisa Gill reinstates PACS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>) with a Overweight and announces $40 price target.

JP Morgan Reinstates Overweight on PACS Group, Announces $40 Price Target

FOLD

Amicus Therapeutics Raises 2024 Total Revenue Growth Guidance From 26% - 31% To 30% - 32% At CER

Allakos perks up after early-stage data for lead asset

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Allakos (ALLK – Research Report), Edwards Lifescie...

Analysts Conflicted on These Healthcare Names: Allakos (ALLK), Edwards Lifesciences (EW) and NewAmsterdam Pharma Company (NAMS)

Jasper gains 11% on data for briquilimab in urticaria

Warning: ALLK is at high risk of performing badly

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

AKBA

ALLK

APVO

CLDX

CNSP

CRMD

CYCC

DBVT

GNPX

IMUX

JSPR

MBIO

NAMS

ONCT

REGN

SGMO

SLRN

SPRY

SYRS

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc.  - ALLK

Legal

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK

Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Allakos Provides Business Update and Reports First Quarter 2024 Financial Results

Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria

Health Care

Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile

Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results

Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers

Comments

Allakos

Allakos (ALLK) Opzioni

Allakos (NASDAQ:ALLK) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO